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Introduction 19
Malaria infection due to Plasmodium falciparum is a major cause of childhood morbidity 20 and mortality in endemic countries. The symptoms of the disease start when the parasite invades 21 and replicates in red blood cells. Upon infection, there are three possible clinical outcomes that 22 are influenced by the host, parasite, and environmental factors: uncomplicated malaria, severe 23 malaria, or asymptomatic parasitemia. The development of asymptomatic parasitemia is largely 24 influenced by adaptive immunity that results from repeated exposures, whereas it is estimated 25 that ~25% of the clinical variation in malaria severity can be explained by innate genetic factors that act additively (MACKINNON et al. 2005) . A variety of studies have shown that one of the 27 strongest protective factors is heterozygosity for the hemoglobin S allele (HbAS), which leads to 28 impaired parasite proliferation at low oxygen tension (PASVOL et al. 1978 berghei ANKA parasites, and protected the mice from cerebral malaria provided some in vivo 46 evidence that GOF mutations in PIEZO1 may influence susceptibility to severe malaria (MA et al. 47 2018) . 48
Using a comparative genomics approach, a common PIEZO1 polymorphism was 49 identified in healthy individuals of African descent that may be under positive selection and act as 50 a gain-of-function allele (MA et al. 2018 ). The mutation, E756del (rs572934641), is a 3 nucleotide 51 deletion in a coding region of the gene that includes ~60 bp of short tandem repeats. PIEZO1
E756del was classified as a gain-of-function mutant based on studies in HEK cells, where it 53 displayed a prolonged inactivation time constant after mechanical stimulation as compared to 54 wild-type PIEZO1. Results from in vitro assays using the human malaria parasite P. falciparum 55 suggested that parasite growth was impaired in RBCs from E756del heterozygotes as compared 56 to wild-type RBCs (MA et al. 2018 ). Together, these findings raise the intriguing possibility that 57 the PIEZO1 E756del allele may be protective against severe malaria in humans. 58
Here, we screened a large case-control study group from Gabon for the PIEZO1 E756del 59 mutation and assessed its impact on the risk of severe malaria. We found that E756del was 60 associated with protection from severe malaria in heterozygotes, suggesting that natural genetic 61 variation in PIEZO1 is an innate determinant of malaria susceptibility in humans. This association 62 was independent of hemoglobin AS, which appears to have an epistatic interaction with PIEZO1 63
E756del. While wild-type and E756del red blood cells supported the intracellular growth of P. 64 falciparum equally well, we found that chemical upregulation of PIEZO1 inhibited P. falciparum 65 replication. PIEZO1 is a druggable ion channel that may be under selective pressure to protect 66 against severe malaria, suggesting that it holds potential as a target for a novel, host-directed 67 therapy for this ancient disease. 68
69
Methods 70
Genetic Association study design and participants 71
Using a case-control approach, we assembled 542 samples from children aged 4-140 72 months that had been obtained in three previously published studies conducted in Lambaréné 73 and Libreville, Gabon (KUN et al. 1998; KALMBACH et al. 2006; KREMSNER et al. 2009 ). After 74 excluding samples for missing parameters, the analytic cohort consisted of 446 samples, of which 75 193 were controls with mild malaria and 253 were cases with severe malaria. All cases presented 76 with microscopically confirmed P. falciparum parasitemia, signs and symptoms of severe malaria 77 and no evidence of other severe diseases. Severe malaria was defined as severe anemia (hemoglobin <50 g/l) and/or hyperparasitemia (>250,000 parasites/μl, corresponding to >10% infected 79 erythrocytes), a Blantyre coma score ≤2 and/or other facultative signs of severe malaria such as 80 cerebral malaria, convulsions, hypoglycemia, and respiratory distress. The control group was those 81 with mild malaria coming from the same geographical area as the cases. Mild malaria was defined 82 as parasitemia 1000-50,000/μl on admission, no schizontemia, circulating leukocytes containing 83 malarial pigment <50/μl, not homozygous for hemoglobin S, hemoglobin >80 g/l, platelets >50/nl, 84 leukocytes <12/nl, lactate <3 mmol/l, and blood glucose >50 mg/dl. Written informed consent for 85 each child was provided by the parents/guardians before enrollment. 86 87
Mutation screening 88
PIEZO1 exon 17 was amplified by PCR using the following primers: 5′-89
CAGGCAGGATGCAGTGAGTG-3′
(forward) and 5′-GGACATGGCACAGCAGACTG-3′ 90 (reverse). Amplification reactions were performed in one batch in the same laboratory. The 91 thermal conditions were an initial denaturation (95°C, 3 min) followed by 35 cycles of 95°C for 30 92 s, 65°C for 30 s and 72°C for 1 min. The PCR was completed with a final extension step of 72°C 93 for 5 min. PCR products were visualized through electrophoresis on a 1·2% agarose gel stained 94 with SYBR Safe DNA Gel Stain (Thermo Fisher Scientific, Waltham, MA, USA). Subsequently, 95 the PCR products were purified with QIAquick PCR purification kit (Qiagen, Hilden, Germany) 96 and directly used as templates for DNA sequencing (Quintara Biosciences, San Francisco, CA, 97 USA). Mutations were identified by aligning the sequences with the PIEZO1 reference sequence 98 (NG_042229.1) using the Geneious 10.2.3 software (Auckland, New Zealand) and visually 99 reconfirmed from their electropherograms. All samples were also genotyped for the HbS 100 polymorphism (rs334) in the HBB gene (NG_059281.1). Briefly, we amplified exon 1 of the HBB 101 gene using the primer pairs: 5′-AGTCAGGGCAGAGCCATCTA-3′ (forward) and 5′-102 GTCTCCACATGCCCAGTTTC-3′ (reverse). The PCR conditions were: initial denaturation (95°C, 103 was completed with a final extension step of 72°C for 5 min. The sequencing and variant detection 105 were performed as described above. 106 107
Statistical analysis 108
Participants with HbSS or HbSC hemoglobin genotypes were excluded from all analyses 109 due to the severity of their underlying hematologic diseases. Additionally, all primary analyses 110 were conducted only on participants without missing observations. Deviation from Hardy-111
Weinberg equilibrium was assessed using Chi-square analysis. Descriptive statistics were 112 generated to evaluate the distributions of key characteristics by malaria severity status. The 113
Wilcoxon rank sum test and Fisher's exact test were used to determine if there were significant 114 differences in malaria severity status in continuous and categorical characteristics, respectively. 115
The primary outcome was an indicator for whether a patient had mild or severe malaria. In order to assess whether HbAS confounds the association between PIEZO1 E756del 127 and malaria severity status, an additional model was fit to malaria severity status as a function of 128 PIEZO1 E756del, HbAS, age, sex, study, and an interaction term between HbAS and PIEZO1 129
E756del. Due to convergence issues based on small sample size, a Bayesian logistic regression model was used (GELMAN ANDREW AND YU-SUNG SU 2018). Similar methods to those used in the 131 main effects model were implemented. Unadjusted logistic models were also fit to assess the 132 association between seven additional PIEZO1 polymorphisms near E756del and severe malaria. 133
Classification trees (CART) were implemented to determine whether a synergistic effect 134 of any PIEZO1 polymorphisms existed in order to predict malaria severity status. CART is a tree-135 based learning technique for classifying observations, which yields a decision rule by partitioning 136 the data into subsets based on variables entered into the algorithm through the minimization of 137 an error function. Two trees were grown to a maximum depth of 3 levels and minimal node size 138 of 4 using the ctree function in the party package in R (HOTHORN et al. 2006) , and included the 139 following features, respectively: 1) all identified PIEZO1 mutations, HbAS, age, and sex; 2) all 140 identified PIEZO1 mutations excluding PIEZO1 E756del, HbAS, age, and sex. To ensure the 141 validity of these models, we conducted a 5 times repeated 10-fold cross-validation (CV) for both 142
CARTs. The CV area under the curve (AUC) and 95% CIs were reported for each tree (KOHAVI 143 1995). Spearman's rank correlation test was also used in order to assess the genetic association 144 (linkage) between PIEZO1 E756del and the other PIEZO1 mutations. 145
As a sensitivity analysis, missing values in age and sex were imputed by chained 146 equations with predictive mean matching in order to assess the robustness of the two PIEZO1 147
E756del logistic regression results (VAN BUUREN AND GROOTHUIS-OUDSHOORN 2011). 148
A p-value < 0·05 was considered statistically significant. All analyses were conducted 149 using R software v3.5.2 (DEVELOPMENT CORE TEAM 2013). 150 151
Blood sample collection and genotyping for in vitro parasite growth assays 152
Subjects who self-identified as African or African-American were recruited to donate blood 153 at the Stanford Clinical Translational Research Unit. All participants and/or their parents gave 154 informed consent according to a protocol approved by the Stanford University IRB (#40479). 155 serum and separate the buffy coat and red blood cells. Red blood cells were washed and stored 157 in RPMI-1640 medium (Sigma) supplemented with 25 mM HEPES, 50 mg/L hypoxanthine, 2.42 158 mM sodium bicarbonate media at 4°C for up to 48 hours, and then cryopreserved in human AB+ 159 serum and glycerol at -80°C. Genomic DNA was isolated from buffy coats using a DNeasy Blood 160
and Tissue Kit (Qiagen). PIEZO1 exon 17 was amplified by PCR of genomic DNA using the 161 primers described above and Q5 polymerase in the following reaction conditions: 98°C for 30 162 seconds initial denaturation followed by 35 cycles of 98°C for 10 seconds, 70°C for 20 seconds, 163 and 72°C for 20 seconds, followed by a 2 minute final extension at 72°C. PCR products were 164 visualized on an agarose gel and sent for Sanger sequencing at Elim Bio (Hayward, CA). The 165 PIEZO1 E756 genotypes were manually determined from chromatograms examined using 166
FinchTV software (Geospiza Inc). All genotypes were assessed by two independent researchers. 167 168 P. falciparum culture and growth assays 169 P. falciparum strain 3D7 is a laboratory-adapted strain that was obtained from the Walter 170 and Eliza Hall Institute (Melbourne, Australia) and was routinely cultured in human erythrocytes 171 obtained from the Stanford Blood Center at 2% hematocrit in RPMI-1640 supplemented with 25 172 mM HEPES, 50 mg/L hypoxanthine, 2.42 mM sodium bicarbonate and 4.31 mg/ml Albumax 173 (Invitrogen) at 37°C in 5% CO2 and 1% O2. Parasite growth assays were initially performed using 174 fresh erythrocytes and then repeated after cryopreservation and thawing. Schizont-stage 175 parasites were isolated using a MACS magnet (Miltenyi) and added at 0.5% initial parasitemia to 176 previously cryopreserved wild-type or E756del heterozygous erythrocytes that had been washed 177 and resuspended in complete RPMI with bicarbonate and Albumax as above. Assays were 178 performed at 0.5% hematocrit in a volume of 100 µl per well in 96-well plates. For drug treatments, 179 erythrocytes were incubated in the indicated concentrations of Yoda-1 (Sigma) for three hours at 180 1% hematocrit and washed in complete RPMI three times before adding to assay plates. 181 SYBR Green 1 nucleic acid stain (Invitrogen, ThermoFisher Scientific, Eugene, OR, USA) at 183 1:2000 dilution in PBS/0.3% BSA for 20 minutes, followed by flow cytometry analysis on a 184
MACSQuant flow cytometer (Miltenyi). 185
For each genetic background (WT versus E756del heterozygote), assays were performed 186 in technical duplicates using seven biological replicates (N=7) from unrelated donors. The percent 187 parasitemia relative to control was determined for each biological replicate by normalizing the 188 parasitemia on day 3 at each drug concentration relative to that in the absence of drug. Then, the 189 for HbSS or HbSC genotypes to minimize confounding effects of severe hematologic disease. A 201 further 88 were excluded due to missing values in sex (n=78) and failure to amplify PIEZO1 202 E756del (n=10). Therefore, our analytic cohort consisted of 446 samples. All samples were from 203
Gabonese children between the ages of 4-140 months; 193 (43%) participants had mild malaria 204 (controls) and 253 (57%) had severe malaria (cases). Cases of severe malaria had severe 205 anemia, hyperparasitemia, signs of cerebral malaria, hypoglycemia and/or respiratory distress in 206 addition to microscopically-confirmed parasitemia. Controls with mild malaria had parasitemia and fever with absence of severe signs. Their baseline demographics are summarized in Table 1 . 208
While cases and controls were similar in terms of sex (45% vs 46% male, respectively), those 209 with severe malaria on average were younger and had higher parasite densities. Differences by 210 study are also summarized (Table S1) . 211
212
The PIEZO1 E756del variant was common among the study population, with a 213 heterozygote prevalence of 36% in controls and 23% in cases (minor allele frequency=0.19). The 214 variant was in Hardy-Weinberg equilibrium in the controls but not in the cases. We used a logistic 215 regression model to predict the probability of severe malaria as a function of PIEZO1 genotype, 216
HbAS status, age, sex and study for each participant. The odds of severe malaria in those with 217 the heterozygous E756del genotype (WT/DEL) were half the odds of those with the homozygous 218 wild-type genotype (OR 0·50, 95% CI 0·31-0·81; p=0·005), suggesting that having one copy of 219 PIEZO1 E756del is protective against severe disease (Table 2 and Table S2 ). Homozygous wild-220 type subjects at E756 (WT/WT) had a significantly higher predicted probability of severe malaria 221 compared to E756del heterozygous (WT/DEL) individuals (median 67% vs. 46%, p=0·01) ( Figure  222   1A) . These results suggest that the E756del variant confers protection for heterozygotes even as 223 to heterozygotes (p=0.02), suggesting that harboring two copies of this mutant allele negates the 226 protective effect observed in carriers ( Figure 1A) . While participants with the homozygous mutant 227 genotype (DEL/DEL) had over twice the odds of severe malaria compared to those who were 228 homozygous wild-type, this association was not statistically significant, likely due to the low overall 229 frequency of the DEL/DEL genotype (OR 2·26, 95% CI 0·82-6·94, p=0·28) ( 
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Association between HbAS and protection from severe malaria 238
As expected, we also found that the sickle cell trait polymorphism (HbAS) was significantly 239 associated with mild malaria in our study population (HbAS vs HbAA, OR 0·27, 95% CI 0·13-0·52; 240 p<0·001) ( Table 2) 
Interplay between PIEZO1 E756del and HbS on malaria severity 247
Because of the high frequencies of both the PIEZO1 E756del variant and HbAS in the 248 study population, we sought to assess whether HbAS confounds the association found for 249
E756del heterozygotes and malaria susceptibility by refitting the main effects model with the 250 addition of an interaction term for HbAS and E756del. For subjects with HbAA, the E756del 251 homozygous wild-type genotype (WT/WT) was associated with a significantly higher probability 252 of severe malaria compared to the E756 heterozygous genotype (WT/DEL) (OR 2·09, 95% CI 253 1·28-3·41; p=0·003, Figure 2 ). In contrast, in subjects with HbAS, heterozygosity for E756del did 254 not alter susceptibility to severe malaria compared to E756 wild-type (p=0·97, Figure 2 and Table  255 S3). These results suggest that the heterozygous PIEZO1 E756del genotype reduces the risk of 256 severe malaria in individuals with normal hemoglobin, but that effect is masked by the strong 257 protective effect of HbAS in those with sickle cell trait. 258
For subjects with HbAA, the odds of severe malaria in those with the E756del 260 heterozygous mutation (WT/DEL) were one third the odds of those with the homozygous mutation 261 (OR 0·33, 95% CI 0·11-0·98; p=0·046, Figure 2 ). While this association was also apparent within 262 individuals with HbAS, a difference in the risk of severe malaria failed to reach statistical 263 significance between the two mutations (p=0·07). This result may suggest that the homozygous 264 mutant E756del genotype alters RBC physiology in a way that abolishes the protective effect of 265
HbAS, and may act with it synergistically to generate an unfavorable environment for controlling 266 malaria infection. However, these results would need to be replicated in larger studies. 267 
Analysis of other proximal PIEZO1 polymorphisms 268
In addition to E756del, we identified seven other single nucleotide polymorphisms and 269 insertion-deletions within the ~160 bp region we sequenced, which ranged in frequency from 0.4% 270 to 7.9% (Table S4 ). Even though these mutations are in close proximity to E756del, none of them 271 were significantly associated with severe malaria individually. To determine whether any of these 272 PIEZO1 variants act synergistically with hemoglobin type, sex or age to influence malaria 273 susceptibility in the absence of E756del, we used classification trees (CART) ( Figure 3A) . For 274 subjects with HbAA, when E756del was excluded, heterozygosity for E750Q appeared protective 275 in younger children, whereas heterozygosity for Q749del was associated with an increased 276 probability of severe malaria in older children. However, correlation testing showed E750Q and 277
Q749del were significantly correlated with E756del, suggesting that these two variants may be 278 serving as a proxy for E756del in predicting malaria severity (results not shown). This hypothesis 279 is further strengthened when the E756del polymorphism is included in the analysis, as no other 280 PIEZO1 variants were predictive of disease severity in the presence of E756del ( Figure 3B) . 281
Together, these results suggest that E756del is the causal variant in this region, and while two of 282 the polymorphisms appeared to predict malaria severity, these may be serving as surrogates for 283
E756del. 
Effect of PIEZO1 E756del on in vitro growth of P. falciparum 291
Previous work suggested that human red blood cells heterozygous for the PIEZO1 292 African descent who are wild-type or heterozygous at PIEZO1 E756del and used their red blood 296 cells in P. falciparum growth assays. To our surprise, we found that P. falciparum replicated 297 equally well in the wild-type versus E756del heterozygous erythrocyte samples (p=0.37, Figure  298 4A). Similar trends were observed when the cells were used freshly or after cryopreservation. 299
These results suggest that while the E756del mutation may confer gain-of-function kinetics (MA 300 et al. 2018), at least in heterozygous RBCs, the phenotype is not strong enough to impair 301 intracellular growth of P. falciparum in vitro. 302
To determine if chemical activation of the PIEZO1 ion channel could inhibit intracellular 303 growth of P. falciparum in RBCs, we used the small synthetic molecule Yoda1, which was recently 304 identified as a specific agonist of both human and mouse PIEZO1 (SYEDA et al. 2015). We 305 observed a dose-dependent effect on P. falciparum growth in both wild-type and E756del RBCs, 306
with an IC50 of ~6 µM ( Figure 4B ). This IC50 concentration is similar to that required for Yoda1 In this work, we sought to determine the clinical relevance of a recent study demonstrating 317 a survival benefit for Plasmodium-infected mice carrying a PIEZO1 gain-of-function allele (MA et 318 al. 2018 ). In the PIEZO1GOF mouse model, the RBCs were dehydrated, intracellular parasite 319 growth was impaired, and the animals were protected from developing cerebral malaria. We 320 assessed the human PIEZO1 mutation E756del, which was identified as a gain-of-function allele 321 based on its prolonged inactivation time constant after mechanical stimulation in HEK cells (MA 322 et al. 2018). Using samples from Gabonese patients with severe or uncomplicated malaria, we 323 found that PIEZO1 E756del is significantly associated with protection against severe malaria. 324
Children heterozygous for E756del had a significantly lower predicted probability of severe 325 malaria compared to those with wild-type PIEZO1, even when controlling for age, sex, and HbAS 326 status. As E756del is present at high frequencies in African populations (MA et al. 2018), these 327 results suggest that it may be a major determinant of innate resistance to severe malaria. Whether 328 this advantage is extended to all severe malaria sub-phenotypes remains to be investigated in 329 the context of a larger study. 
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Given the strong protective effect of PIEZO1 E756del on severe malaria in our study, its 331 absence from GWAS candidate lists is particularly notable. The sensitivity of GWAS studies for 332 malaria in Africa are limited by several factors, including weak linkage disequilibrium and 333 population stratification (JALLOW et al. 2009 ), as well as technical limitations in assessing complex 334 or repetitive regions via microarrays or deep sequencing. The PIEZO1 E756del mutation is a 335 three nucleotide deletion within a region of short tandem repeats, making it difficult to detect by 336 high-throughput methods. In our study, accurate genotyping of this locus required Sanger 337 sequencing and manual alignments. These studies on PIEZO1 highlight the benefit of using a 338 combination of sequencing methods for the identification of host factors that may influence 339 susceptibility to malaria. 340
The finding that E756del is protective against severe malaria only in heterozygotes is 341 in RBCs can inhibit P. falciparum growth, one explanation for the lack of a phenotype in untreated 385
E756del heterozygous RBCs could be that E756del confers only a mild channel defect. Indeed, 386 out of two candidates and one established PIEZO1 GOF mutation tested, E756del displayed the 387 shortest channel inactivation time (MA et al. 2018) . As the experiments measuring channel 388 kinetics were performed using ectopic expression in HEK cells, it is possible that the channel 389 phenotype of E756del in heterozygous RBCs is even more mild. This conclusion is further 390 supported by our findings showing that wild-type and E756del RBCs were equally sensitive to 391
Yoda1's antimalarial activity. Previous work in mice showed that Yoda1 is specific for PIEZO1, as 392 it induced cation permeability and cellular dehydration in wild-type but not PIEZO1-null mouse 393
RBCs (CAHALAN et al. 2015) . Bioinformatic analyses aimed at identifying mechanosensitive 394 channels in pathogenic protozoa did not identify any homologues of PIEZO1 in Apicomplexan 395 parasites, making it unlikely that Yoda1 could be acting on a parasite-encoded target (PROLE AND 396 TAYLOR 2013). In our experiments, we further minimized this possibility by pre-incubating the 397 RBCs in Yoda1 for several hours and then washing the cells extensively before infecting with 398
parasites. 399
Given that in vitro growth of P. falciparum in RBCs is unaffected by PIEZO1 E756del, how 400 might this common polymorphism protect from severe malaria? As with many life-threatening 401 systemic infections, the symptoms of severe malaria are in large part caused by the body's 402 extreme response to overwhelming infection by a microorganism. Additionally, the adhesive 403 properties of P. falciparum-infected RBCs enable them to sequester in the deep microvasculature 404 and adhere to uninfected RBCs, exacerbating organ dysfunction. As PIEZO1 is expressed in 405 many tissues including the vascular endothelium and immune cells, it is possible that 406 dysregulation of its channel activity has effects on vascular tone, cell permeability and/or signaling 407 during malaria infection that are independent of any effects on RBCs. Alternatively, E756del may 435
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